We review innovative methods for treatment of cancer tumor on the basis of nanotechnology and physics to target, monitor and control release of chemotherapeutic agents. Chemotherapy is one of the main methods of treatment for cancer and plays a vital role in clinical practice, but side effects of anticancer drugs are still critical problems. Magnetic nanoparticles can be applied as an effective drug carriers and contrast agents for magnetic resonance imaging (MRI). Since certain nanoparticles have magnetic properties, they can be trapped in tumor during blood circulation by an external magnetic field. Also, polymeric nanoparticles are great candidates to encapsulate anticancer drugs and to control the release profile of drugs in biologic media. We suggest the construction of drug-loaded polymer-coated magnetic (DPM) nanoplatform with the potential for being utilized in medical imaging as well as having controlled drug release properties. Nanoplatform distribution can be monitored by MRI and with clever combination of ultrasound physics and suggested DPM nanoplatform, it would be feasible to increase the rate of drug release (in situ) and drug uptake by cancerous cell. To optimize the level of drug uptake by cancerous cell, the selection of ultrasound frequency and intensity is essential. The development of suggested method could be a new approach against cancer tumor. 1. Introduction 1.1. Cancer Cancer is a disease of the cell in which the normal mechanisms of cell growth and proliferation are disturbed. Among all treatments for cancer (surgery, chemotherapy, and radiotherapy), chemotherapy plays an important role in clinical practice, but the drugs’ side effects are the main problems [1, 2]. Anticancer agents are not specific to just targeting cancer cells and always lead to systemic toxicity. As a result, these drugs cause undesirable and severe side effects such as hair loss, renal and hepatic damages, and bone marrow [3]. Therefore, one of the major disadvantages of the chemotherapy is the destruction of cancer cells as well as normal cells of the body. This difficulty would be minimized if we concentrate the drug in the tumor region which in turn leads to the increase of antitumor efficacy with applying a locally higher but systemically lower dose. Also from economical point of view, administrating a lower dose drugs systematically can be taken into consideration. Accordingly, an exciting potential solution for this problem is to encapsulate the drug in biocompatible and biodegradable materials that can be injected into the blood stream with the
References
[1]
G. Ali Mansoori, K. S. Brandenburg, and A. Shakeri-Zadeh, “A comparative study of two folate-conjugated gold nanoparticles for cancer nanotechnology applications,” Cancers, vol. 2, no. 4, pp. 1911–1928, 2010.
[2]
Y. Zhang, B. Wang, Y. Wang, W. Qiao, and P. Shao, “A novel hypurgia for cancer chemotherapy: programmable release of antineoplastics and cytothesis agents from core-shell micro-/nano-particles,” Medical Hypotheses, vol. 76, no. 2, pp. 201–203, 2011.
[3]
J. R. Senior, “Unintended hepatic adverse events associated with cancer chemotherapy,” Toxicologic Pathology, vol. 38, no. 1, pp. 142–147, 2010.
[4]
G. Ciofani, C. Riggio, V. Raffa, A. Menciassi, and A. Cuschieri, “A bi-modal approach against cancer: magnetic alginate nanoparticles for combined chemotherapy and hyperthermia,” Medical Hypotheses, vol. 73, no. 1, pp. 80–82, 2009.
[5]
A. Jordan, P. Wust, H. Fahling, W. John, A. Hinz, and R. Felix, “Inductive heating of ferrimagnetic particles and magnetic fluids: physical evaluation of their potential for hyperthermia,” International Journal of Hyperthermia, vol. 9, no. 1, pp. 51–68, 1993.
[6]
J. Siepmann, N. Faisant, J. Akiki, J. Richard, and J. P. Benoit, “Effect of the size of biodegradable microparticles on drug release: experiment and theory,” Journal of Controlled Release, vol. 96, no. 1, pp. 123–134, 2004.
[7]
C. Alexiou, R. Jurgons, R. J. Schmid et al., “Magnetic drug targeting—biodistribution of the magnetic carrier and the chemotherapeutic agent mitoxantrone after locoregional cancer treatment,” Journal of Drug Targeting, vol. 11, no. 3, pp. 139–149, 2003.
[8]
A.-J. Lemke, M.-I. Senfft von Pilsach, A. Lübbe, C. Bergemann, H. Riess, and R. Felix, “MRI after magnetic drug targeting in patients with advanced solid malignant tumors,” European Radiology, vol. 14, no. 11, pp. 1949–1955, 2004.
[9]
K. Mosbach and U. Schroder, “Preparation and application of magnetic polymers for targeting of drugs,” FEBS Letters, vol. 102, no. 1, pp. 112–116, 1979.
[10]
M. Ashjari, S. Khoee, and A. R. Mahdavian, “A multiple emulsion method for loading 5-fluorouracil into a magnetite-loaded nanocapsule: a physicochemical investigation,” Polymer International, vol. 61, no. 5, pp. 850–859, 2012.
[11]
M. B. Shiran, M. Motevalian, R. Ravanfar, and S. Bohlooli, “The effect of bubble surface charge on phonophoresis: implication in transdermal piroxicam delivery,” Iranian Journal of Pharmacology and Therapeutics, vol. 7, no. 1, pp. 15–19, 2008.
[12]
I. V. Larina, B. M. Evers, T. V. Ashitkov, C. Bartels, K. V. Larin, and R. O. Esenaliev, “Enhancement of drug delivery in tumors by using interaction of nanoparticles with ultrasound radiation,” Technology in Cancer Research and Treatment, vol. 4, no. 2, pp. 217–226, 2005.
[13]
N. Y. Rapoport, D. A. Christensen, H. D. Fain, L. Barrows, and Z. Gao, “Ultrasound-triggered drug targeting of tumors in vitro and in vivo,” Ultrasonics, vol. 42, no. 1–9, pp. 943–950, 2004.
[14]
Y. Liu, H. Miyoshi, and M. Nakamura, “Nanomedicine for drug delivery and imaging: a promising avenue for cancer therapy and diagnosis using targeted functional nanoparticles,” International Journal of Cancer, vol. 120, no. 12, pp. 2527–2537, 2007.
[15]
N. Y. Rapoport, A. M. Kennedy, J. E. Shea, C. L. Scaife, and K.-H. Nam, “Controlled and targeted tumor chemotherapy by ultrasound-activated nanoemulsions/microbubbles,” Journal of Controlled Release, vol. 138, no. 3, pp. 268–276, 2009.
[16]
C.-Y. Lin, Y.-L. Huang, J.-R. Li, F.-H. Chang, and W.-L. Lin, “Effects of focused ultrasound and microbubbles on the vascular permeability of nanoparticles delivered into mouse tumors,” Ultrasound in Medicine and Biology, vol. 36, no. 9, pp. 1460–1469, 2010.
[17]
A. S. Lübbe, C. Alexiou, and C. Bergemann, “Clinical applications of magnetic drug targeting,” Journal of Surgical Research, vol. 95, no. 2, pp. 200–206, 2001.
[18]
C. Alexiou, W. Arnold, R. J. Klein et al., “Locoregional cancer treatment with magnetic drug targeting,” Cancer Research, vol. 60, no. 23, pp. 6641–6648, 2000.
[19]
A. Schroeder, R. Honen, K. Turjeman, A. Gabizon, J. Kost, and Y. Barenholz, “Ultrasound triggered release of cisplatin from liposomes in murine tumors,” Journal of Controlled Release, vol. 137, no. 1, pp. 63–68, 2009.
[20]
J. Kruskal, S. Goldberg, and R. Kane, Eds., Novel In Vivo Use of Conventional Ultrasound to Guide and Enhance Molecular Delivery and Uptake into Solid Tumors, 2001.
[21]
A. Shakeri-Zadeh, G. A. Mansoori, A. R. Hashemian, H. Eshghi, A. Sazgarnia, and A. R. Montazerabadi, “Cancerous cells targeting and destruction using folate conjugated gold nanoparticles,” Dynamic Biochemistry, Process Biotechnology and Molecular Biology, vol. 4, pp. 6–12, 2010.
[22]
A. Hashemian, H. Eshghi, G. Mansoori, A. Shakeri-Zadeh, and A. Mehdizadeh, “Folate-conjugated gold nanoparticles (synthesis, characterization and design for cancer cells nanotechnology-based targeting),” International Journal of Nanoscience and Nanotechnology, vol. 5, no. 1, article 25, 2010.
[23]
A. Shakeri-Zadeh, M. Ghasemifard, and G. Ali Mansoori, “Structural and optical characterization of folate-conjugated gold-nanoparticles,” Physica E: Low-Dimensional Systems and Nanostructures, vol. 42, no. 5, pp. 1272–1280, 2010.
[24]
A. Shakeri-Zadeh, H. Eshghi, G. A. Mansoori, and A. R. Hashemian, “Gold nanoparticles conjugated with folic acid using mercaptohexanol as the linker,” Journal Nanotechnology Progress International, vol. 1, pp. 13–23, 2009.
[25]
K. S. Brandenburg, A. Shakeri-Zadeh, R. Hashemian, and G. A. Mansoori, “Folate-conjugated gold nanoparticles for cancer nanotechnology applications,” in Proceedings of Nanotechnology Conference, pp. 404–407, June 2011.
